Selected Grants
An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Clinical TrialCo Investigator · Awarded by Eidos Therapeutics · 2026 - 2030Metabolic and contractile dysfunction in HFpEF
ResearchCo Investigator · Awarded by National Institutes of Health · 2026 - 2030A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in irondeficient subjects with symptomatic chronic heart failure
Clinical TrialCo-Principal Investigator · Awarded by Pharmacosmos Therapeutics Inc. · 2026 - 2029Diversifying Recruitment to Improve Generalizability of Therapeutic Ketosis Strategies in Heart Failure
ResearchPrincipal Investigator · Awarded by Medical College of Virginia Foundation · 2025 - 2028Probing Regional Metabolism During Exercise through Coronary Sinus Sampling
ResearchPrincipal Investigator · Awarded by National Heart, Lung, and Blood Institute · 2025 - 2027Dissecting the Ketone Metabolic Axis in Heart Failure with Reduced Ejection Fraction
ResearchPrincipal Investigator · Awarded by National Heart, Lung, and Blood Institute · 2022 - 2027AFAR Finding Aging Biomarkers by Searching existing Trials (FAST) Initiative
ResearchCo-Principal Investigator · Awarded by Columbia University · 2026 - 2027Reactive Oxygen Species and Respiratory Muscle Dysfunction in Heart Failure
ResearchCo-Mentor · Awarded by National Heart, Lung, and Blood Institute · 2024 - 2027Impact of Exogenous Ketone Therapy on Skeletal Muscle Fuel Substrates After Exercise in HFrEF
ResearchPrincipal Investigator · Awarded by American Heart Association · 2026 - 2027A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants with Heart Failure with Preserved Ejection Fraction HFpEF
Clinical TrialCo Investigator · Awarded by Bristol-Myers Squibb Company · 2025 - 2026Dissecting the Ketone Metabolic Axis in Heart Failure with Reduced Ejection Fraction
ResearchPrincipal Investigator · Awarded by American Heart Association · 2022 - 2026Diagnostic Utility of SGLT2 Inhibition to Facilitate Myocardial Glucose Suppression During Evaluation of Cardiac Inflammation on FDG-PET
Clinical TrialPrincipal Investigator · Awarded by The Foundation for Sarcoidosis Research · 2024 - 2026Columbia - Impetus: Finding Aging biomarkers by Searching existing Trials (FAST) Initiative
ResearchCo-Principal Investigator · Awarded by Columbia University · 2025 - 2025External Relationships
- American Heart Association
- AstraZeneca
- BridgeBio
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.